News Release

Elderly getting left out of critical cancer research

And are not being offered the best treatment options

Peer-Reviewed Publication

Shire Health New York

- experts attending international conference on older cancer patients want new research, and treatment equity -

Boston, MA (September 30, 2002) Despite the median age of cancer patients reaching seventy years old, leading oncology experts from around the world say elderly patients are often excluded from important clinical trials and are not being offered the same treatment options as younger patients.

The experts, attending the 7th International Conference on Geriatric Oncology, have called for equity in access to treatment options and additional research among elderly cancer patients. New research is particularly needed in elderly patients with co-morbid conditions, such as heart disease, and in those taking multiple medications that can often interact adversely with one another.

"Cancer is an increasingly important problem in the elderly, yet there is a lack of research focusing on this important group," said Dr. Paul Calabresi of Providence, Rhode Island and president of the International Society of Geriatric Oncology. "In the next ten years there will be an exponential increase in patient numbers. We can no longer ignore this important patient population," Calabresi added.

Commenting on the issue of access to treatments, Dr. Silvio Monfardini (Padore, Italy), future president of SIOG said, "Elderly cancer patients must be offered the same treatment options as younger patients, even if treatment of the elderly is less cost-effective."

"It is wrong and unethical to discriminate against a patient because of their age," Mondfardini concluded.

Highlights of the conference include Dr. Matti Aapro's (Clinique De Genolier, Switzerland) presentation on the guidelines for treating anemia in elderly cancer patients. When discussing patient care, Dr. Aapro states there is a clear need to continue the pioneering work of the U.S. National Cancer Network, demonstrating that all elderly patients need to be treated appropriately in order to ensure normal hemoglobin levels.

In addition, Dr. Lazzaro Repetto (Instituto Nazionale di Riposo e Cura per Anziani) presented on the use of the European Organization for Research and Treatment of Cancer Task Force in the Elderly (EORTC-TFE) guidelines on hematopoietic growth factors. Dr. Repetto also confirmed that the U.S. guidelines for the use of G-CSF (a white blood cell growth factor) are valid for elderly patients.

The International Society of Geriatric Oncology is dedicated to advance the art, science and practice of oncology in elderly patients and to disseminate knowledge in order to maintain a high common standard of healthcare in elderly cancer patients.

For additional information about the SIOG meeting in Boston, visit their website @ www.cancerworld.org/siog

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.